肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

SITC 2015：聚焦国际肿瘤免疫治疗前沿趋势

2015-11-07 MedSci MedSci原创

肿瘤免疫治疗
关注

2015年第30届癌症免疫治疗协会年会（SITC）于11月4日-8日在美国——马里兰州——国家港口召开； CAR-T细胞治疗现状：安全性及疗效 肿瘤免疫疗法的疗效评价 FDA加速免疫治疗审批程序 Public Accessto CBER 结论：1.新的治疗方法带来新的监管挑战； 2.个体化治疗（精准治疗）需要新的临床dev


2015年第30届癌症免疫治疗协会年会（SITC）于11月4日-8日在美国——马里兰州——国家港口召开；


CAR-T细胞治疗现状：安全性及疗效


肿瘤免疫疗法的疗效评价


FDA加速免疫治疗审批程序


Public Accessto CBER

结论：

1.新的治疗方法带来新的监管挑战；

2.个体化治疗（精准治疗）需要新的临床development paradigms；

3.肿瘤缩小（反应率）或许不能真正预测临床获益；

4.基因修饰T细胞，扩增，目前剂量，安全性挑战。


基于基因/细胞的肿瘤治疗产品（2009-2014）

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2016-08-27 智慧医人

    #SIT#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-12 静秋

    免疫治疗是未来一个趋势，但价格昂贵。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 huangwukui

    搞不懂，多学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 medcardio

    肿瘤缩小（反应率）或许不能真正预测临床获益；

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 1ddeea37m96(暂无匿称)

    免疫疗法看来是大有可为

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 IIIi

    不够详细

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 pharmxing

    谢谢！希望有更多更新更权威的数据公布

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 sanshengshi

    赞

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1910473, encodeId=600019104e355, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Aug 27 04:35:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43035, encodeId=1f9e4303574, content=免疫治疗是未来一个趋势，但价格昂贵。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ec41662774, createdName=静秋, createdTime=Thu Nov 12 08:16:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42861, encodeId=f58442861e1, content=搞不懂，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Nov 08 18:59:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42844, encodeId=59e042844d1, content=肿瘤缩小（反应率）或许不能真正预测临床获益；, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sun Nov 08 14:40:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42836, encodeId=294f4283672, content=免疫疗法看来是大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9a1661810, createdName=1ddeea37m96(暂无匿称), createdTime=Sun Nov 08 14:21:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42823, encodeId=b9af42823db, content=不够详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8aa11659262, createdName=IIIi, createdTime=Sun Nov 08 11:16:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42803, encodeId=93504280326, content=谢谢！希望有更多更新更权威的数据公布, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Sun Nov 08 09:07:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42801, encodeId=a93842801c3, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sun Nov 08 09:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42797, encodeId=a98a42e977e, content=肿瘤治疗大有可为, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Sun Nov 08 08:02:00 CST 2015, time=2015-11-08, status=1, ipAttribution=)]
    2015-11-08 cyzj007

    肿瘤治疗大有可为

    0

相关资讯

Cell：内质网应激关键蛋白调节抗肿瘤免疫

近日，来自美国的研究人员在著名国际学术期刊Cell在线发表了一项最新研究进展，他们发现内质网应激应答因子XBP1能够通过调节脂质代谢影响DC细胞功能，抑制T细胞抗肿瘤免疫，促进肿瘤进展，为肿瘤免疫治疗的发展提供了一个重要线索。   本文亮点：   ●肿瘤微环境中的DC细胞存在ER应激和IRE1a/XBP1激活 ●DC细胞内的XBP1能够驱动原位和转移性卵巢癌进展

Bellicum建立肿瘤免疫疗法工厂

CAR-T疗法是目前的肿瘤疗法明星，其出色的疗效令许多产业人士和投资者所瞩目。随着数年的研究，这一疗法已经日趋成熟。许多进入这一领域的生物医药公司都开始考虑CAR-T疗法量产的问题。 最近，在肿瘤免疫疗法研究领域中颇为活跃的Bellicum Pharmaceuticals宣布公司已经决定自己建立一处专门用于生产细胞疗法相关产品的工厂。这处总面积达27000平方英尺的工厂位于Bellicum公司的

CSCO 2015：肿瘤免疫治疗：肿瘤治疗的未来趋势

恶性肿瘤是目前全世界的主要死亡原因之一，已经成为严重危害人类生命健康、制约社会经济发展的一大类疾病。《2014年全球癌症报告》称2012年全球癌症患者和死亡病例都在令人不安地增加，新增癌症病例有近一半出现在亚洲，其中大部分在中国，中国新增癌症病例高居第一位。在肝、食道、胃和肺等4种恶性肿瘤中，中国新增病例和死亡人数均居世界首位。 在日前召开的第十八届全国临床肿瘤学大会暨 2015 年

赛诺菲重金布局新一代口服小分子肿瘤免疫疗法

肿瘤免疫疗法是肿瘤治疗领域的一种新兴治疗方法，通过增强人体的免疫机能来抵御癌症，其中最令人瞩目的当属PD-1/PD-L1检查点抑制剂，这是一类注射型抗体药物，通过阻断PD-1/PD-L1信号通路使癌细胞死亡，具有治疗多种类型肿瘤的潜力，有望实质性改善患者的生存。 目前，PD-1/PD-L1免疫竞赛异常激烈，市场峰值高达350亿美元，该领域佼佼者包括百时美施贵宝、默沙东、罗氏、阿斯利康。其中，

Cell：阿司匹林为肿瘤免疫治疗添动力

根据一项发表在著名国际学术期刊cell上的最新研究，在进行肿瘤免疫治疗的同时服用阿司匹林可以大大提高治疗效果。来自英国弗朗西斯克里克研究所的研究人员们通过研究证明皮肤癌，乳腺癌和大肠癌细胞经常会产生大量前列腺素E2（PGE2），这种分子能够减弱免疫系统对病变细胞的正常应答，帮助癌细胞进行隐藏，这一过程使得肿瘤能够快速生长，也部分解释了为什么一些免疫治疗方法不能达到预期效果。阿司匹林是COX抑制剂的

Nature：树突状细胞分子刹车在抗肿瘤免疫中的作用

在小鼠的卵巢癌模型中，激活树突状细胞的应激反应和转录因子XBP1，能抑制树突状细胞抗肿瘤免疫的作用。 肿瘤微环境中的细胞时刻暴露于各种刺激之下。这部分可归因于缺氧和缺乏营养导致的内质网功能失常。内质网是负责蛋白质折叠的细胞器。内质网功能失调后，细胞内错误折叠蛋白堆积——也就是所谓的内质网应激。癌症细胞通过内质网应激能从缺氧缺营养的环境中生存下来。科学家们目前仍不清楚，这条通路是否影响肿瘤微